Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer

Table 3 Comparison of serum-related index levels between the two groups

Group	VEGF (pg/mL)		MMP-9 (mg/L)		COX-2 (ng/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 43), mean ± SD	421.38 ± 36.41	375.60 ± 22.05a	301.25 ± 26.73	256.78 ± 17.62a	711.39 ± 54.43	523.41 ± 27.48a
Observation group (n = 39), mean ± SD	427.91 ± 37.23	294.81 ± 20.63a	308.43 ± 22.08	200.43 ± 15.02a	718.43 ± 49.26	311.36 ± 22.14a
t	0.802	17.083	1.318	15.504	0.612	38.227
P value	0.425	< 0.001	0.191	< 0.001	0.542	< 0.001

^aP < 0.05 vs before treatment in the same group. VEGF: Vascular endothelial growth factor; MMP-9: Matrix metalloprotein-9; COX-2: Cyclooxygenase-2.